Drug Profile
Rilpivirine - Janssen
Alternative Names: Edurant; EDURANTPED; G002 - Janssen Therapeutics; G007; G009-01; JNJ-16150108; Long-acting TMC278; R 278474; Rekambys; Rilpivirine hydrochloride; TMC 278; TMC-278-A; TMC278 LA (IM injection) - Tibotec; TMC278LALatest Information Update: 26 Apr 2024
Price :
$50
*
At a glance
- Originator Tibotec Pharmaceuticals
- Developer Janssen R&D Ireland; Janssen Sciences Ireland UC; Janssen Therapeutics; National Institute of Allergy and Infectious Diseases; PATH; ViiV Healthcare
- Class Antiretrovirals; Nitriles; Pyrimidines; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed HIV-1 infections
Most Recent Events
- 24 Apr 2024 Launched for HIV-1 infections (In adolescents, Treatment-naive) in USA (PO)
- 19 Mar 2024 Launched for HIV-1 infections (Combination therapy, In children, Treatment-naive) in USA (PO)
- 19 Mar 2024 Registered for HIV-1 infections (Combination therapy, In children, Treatment-naive) in USA (PO)